Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;71(2):357-364.
doi: 10.1007/s12020-020-02548-2. Epub 2021 Jan 4.

Insulin-degrading enzyme higher in subjects with metabolic syndrome

Y Sofer #  1 , Y Nash #  2   3 , E Osher  4 , O Fursht  2 , G Goldsmith  2 , L Nahary  5 , S Shaklai  4 , K M Tordjman  4 , M Serebro  4 , E B Touati  4 , M Yacobi Bach  4 , Y Marcus  4 , B Tal  4 , J Sack  4 , G Shefer  4 , M Margaliot  4 , N Landis  4 , I Goldiner  6 , W Abu Ahmad  7 , N Stern  4 , I Benhar  5 , D Frenkel  8   9
Affiliations

Insulin-degrading enzyme higher in subjects with metabolic syndrome

Y Sofer et al. Endocrine. 2021 Feb.

Abstract

Metabolic syndrome (MS) is comprised of a cluster of abnormalities in glucose, lipid, and vascular homeostasis, which is most commonly linked to abdominal obesity. MS heralds increased risk for development of diabetes and is linked to impairment in insulin signaling. Insulin-degrading enzyme (IDE) is one of the mechanisms through which insulin blood levels are maintained. It has been previously suggested that controlling IDE levels could provide yet another potential therapeutic approach in diabetes. Here we aim to investigate whether changes in serum IDE levels correlate with the severity of MS. Using a highly sensitive ELISA assay of active IDE in human serum, we found a strong correlation between circulating IDE levels and circulating levels of triglycerides, insulin, and c-peptide and an inverse correlation with HDL cholesterol (HDLc). Serum IDE levels were higher in MS subjects than in control subjects. Hence, circulating IDE may serve as a tool to identify subjects with abnormal insulin metabolism, possibly those with MS that are at risk to develop diabetes.

Keywords: Insulin Degradation; Insulin Resistance; Metabolic Syndrome; Prediabetes.

PubMed Disclaimer

References

    1. S.L. Samson, A.J. Garber, Metabolic syndrome. Endocrinol. Metab. Clin. North Am. 43(1), 1–23 (2014) - DOI
    1. R.H. Eckel, K.G. Alberti, S.M. Grundy, P.Z. Zimmet, The metabolic syndrome. Lancet 375(9710), 181–183 (2010) - DOI
    1. S.M. Grundy, Metabolic syndrome update. Trends Cardiovasc. Med. 26(4), 364–373 (2016) - DOI
    1. W.C. Duckworth, R.G. Bennett, F.G. Hamel, Insulin degradation: progress and potential. Endocr. Rev. 19(5), 608–624 (1998) - PubMed
    1. J.P. Maianti, A. McFedries, Z.H. Foda, R.E. Kleiner, X.Q. Du, M.A. Leissring, W.J. Tang, M.J. Charron, M.A. Seeliger, A. Saghatelian et al. Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones. Nature 511(7507), 94–98 (2014) - DOI

Publication types

LinkOut - more resources